The role of new agents in the treatment of non-small cell lung cancer

European Journal of Cancer

Volumn 38, Issue 18, 2002, Pages 2347-2361

  Bröker, Linda E ^a   Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; New agents; NSCLC; Treatment

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ACETYLSALICYLIC ACID; AE 941; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANERTINIB; CARBOPLATIN; CETUXIMAB; CGP 69846A; DOCETAXEL; EPOTHILONE B; EPOTHILONE DERIVATIVE; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; INDOMETACIN; ISIS 2503; ISIS 3521; IXABEPILONE; L 778123; LAPATINIB; LONAFARNIB; MARIMASTAT; MATUZUMAB; PACLITAXEL; PRINOMASTAT; REBIMASTAT; SABARUBICIN; SEMAXANIB; SQUALAMINE; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EPISTAXIS; FATIGUE; GASTROINTESTINAL DISEASE; GENE REPLACEMENT THERAPY; HEADACHE; HEART DISEASE; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING;

EID: 0036892178     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00457-4     Document Type: Article

References (240)

1. Travis W.D., Colby T.V., Corrin B. World Health Organization Classification of Lung and Pleural Tumors, 3rd Edn. 1999;Springer-Verlag, Berlin.
2. American joint Committee on Cancer. AJCC Cancer Staging Manual, 5th Edn. Baltimore, Lippincott Williams & Wilkins, 1997, 127.
3. Manegold C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer. 34(Suppl 2):2001;S165-S170.
4. Schiller J.H., Harrington D., Belani C.P.et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:2002;92-98.
5. Anonymous. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311, 899-909.
6. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer. how much benefit is enough? J Clin Oncol. 11:1993;1866-1872.
7. Carney D.N. Lung cancer-time to move on from chemotherapy. N Engl J Med. 346:2002;126-128.
8. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 17:1999;1061-1070.
9. Bollag D.M., McQueney P.A., Zhu J.et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55:1995;2325-2333.
10. Kowalski R.J., Giannakakou P., Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem. 272:1997;2534-2541.
11. Calvert PM, O'Neill V, Twelves C, et al. A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 429).
12. Chen T, Twelves C, Calvert AH, et al. Pharmacokinetics (PK) of EPO906 in cancer patients (pts) receiving EPO906 by a short intravenous infusion once every 3 weeks. Proc Am Soc Clin Oncol 2002, 21(abstract No. 363).
13. Mani S, McDaid H, Shen H, et al. Phase I pharmacokinetic and pharmacodynamic study of an epothilone B analog (BMB-247550) administered as a 1-hour infusion every 3 weeks: An update. Proc Am Soc Clin Oncol 2002, 21(abstract No. 409).
14. Agrawal M, Kotz H, Abraham J, et al. A phase I clinical trial of BMS 247550 (NSC 71028), an epothilone B derivative, in patients with refractory neoplasms. Proc Am Soc Clin Oncol 2002, 20(abstract No. 410).
15. Tripathi R, Gadgeel SM, Wozniak AJ, et al. Phase I clinical trial of BMB-247550 (epothilone B derivative) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21(abstract No. 407).
16. Delbaldo C, Lara PN, Vansteenkiste J, et al. Phase II study of the novel epothilone BMS-247550 in patients (pts) with recurrent or metastatic non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1211).
17. Roche H, Delord JP, Bunnell CA, et al. Phase II studies of the novel epothilone BMS-247550 in patients (pts) with taxane-naïve or taxane-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 223).
18. Seker H., Bertram B., Burkle A.et al. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br J Cancer. 82:2000;629-634.
19. Pohl J., Bertram B., Hilgard P., Nowrousian M.R., Stuben J., Wiessler M. D-19575 - a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol. 35:1995;364-370.
20. Veyhl M., Wagner K., Volk C.et al. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci USA. 95:1998;2914-2919.
21. Briasoulis E., Judson I., Pavlidis N.et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol. 18:2000;3535-3544.
22. Depenbrock H, Dumez H, Van Oosterom AT, Schieback S, Schuessler M, Hanauske AR. Phase I clinical and pharmacokinetic study of glufosfamide administered as short time infusion every three weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 468).
23. Giaccone G, De Jonge E, Dansin N, et al. Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in non-small cell lung cancer. Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2001 (abstract 706).
24. Pronzato P., Vigani A., Tognoni A., Vaira F., Canessa P. Anthracyclines in non-small cell lung cancer. Lung Cancer. 34(Suppl 4):2001;S57-S59.
25. Pratesi G., Monestiroli S.V. Preclinical evaluation of new anthracyclines. Curr Med Chem. 8:2001;9-13.
26. Arcamone F., Animati F., Berettoni M.et al. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst. 89:1997;1217-1223.
27. Cirillo R., Sacco G., Venturella S., Brightwell J., Giachetti A., Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol. 35:2000;100-108.
28. Gonzalez-Paz O., Polizzi D., De Cesare M.et al. Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice. Eur J Cancer. 37:2001;431-437.
29. Minotti G., Parlani M., Salvatorelli E.et al. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol. 134:2001;1271-1278.
30. Pratesi G., De Cesare M., Caserini C.et al. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clin Cancer Res. 4:1998;2833-2839.
31. Bos A.M., de Vries E.G., Dombernovsky P.et al. Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol. 48:2001;361-369.
32. Schrijvers D., Bos A.M., Dyck J.et al. Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol. 13:2002;385-391.
33. Fukushima M., Satake H., Uchida J.et al. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 13:1998;693-698.
34. Fukushima M., Shimamoto Y., Kato T.et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 9:1998;817-823.
35. Van Groeningen C.J., Peters G.J., Schornagel J.H.et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 18:2000;2772-2779.
36. Furuse K., Kawahara M., Hasegawa K.et al. Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol. 6:2001;236-241.
37. Kawahara M., Furuse K., Segawa Y.et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:2001;939-943.
38. Aaronson S.A. Growth factors and cancer. Science. 254:1991;1146-1153.
39. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232.
40. Arteaga C.L. The epidermal growth factor receptor. from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia J Clin Oncol. 19:2001;32. S-40S.
41. Klapper L.N., Glathe S., Vaisman N.et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 96:1999;4995-5000.
42. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network. receptor heterodimerization in development and cancer EMBO J. 19:2000;3159-3167.
43. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56:1987;881-914.
44. Carpenter G., Cohen S. Epidermal growth factor. J Biol Chem. 265:1990;7709-7712.
45. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., Bunn P.A.J. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 29:2002;3-14.
46. Cox G., Jones J.L., O'Byrne K.J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 6:2000;2349-2355.
47. Ohsaki Y., Tanno S., Fujita Y.et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 7:2000;603-607.
48. Selvaggi G, Scagliotti GV, Novello S, et al. Prospective evaluation of epidermal growth factor (EGFR) expression in completely resected non-small cell lung cancer (NSCLC): Effects of EGFR on long term follow up. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1345).
49. Swinson DE, Cox G, Jones JL, et al. Activated epidermal growth factor receptor (EGFR) correlates with a poor prognosis in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1208).
50. Veale D., Kerr N., Gibson G.J., Kelly P.J., Harris A.L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 68:1993;162-165.
51. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 77:1998;663-669.
52. D'Amico T.A., Massey M., Herndon J.E., Moore M.B., Harpole D.H.J. A biologic risk model for stage I lung cancer. immunohistochemical analysis of 408 patients with the use of ten molecular markers J Thorac Cardiovasc Surg. 117:1999;736-743.
53. Dazzi H., Hasleton P.S., Thatcher N.et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer. 59:1989;746-749.
54. Fontanini G., De Laurentiis M., Vignati S.et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 4:1998;241-249.
55. Greatens T.M., Niehans G.A., Rubins J.B.et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 157:1998;1093-1097.
56. Pastorino U., Andreola S., Tagliabue E.et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 15:1997;2858-2865.
57. Pfeiffer P., Clausen P.P., Andersen K., Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer. an immunohistochemical study on cryosections Br J Cancer. 74:1996;86-91.
58. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 3:1997;515-522.
59. Hirsch F.R., Franklin W.A., Veve R., Varella-Garcia M., Bunn P.A.J. HER2/neu expression in malignant lung tumors. Semin Oncol. 29:2002;51-58.
60. Arteaga C.L., Winnier A.R., Poirier M.C.et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 54:1994;3758-3765.
61. Brabender J., Danenberg K.D., Metzger R.et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 7:2001;1850-1855.
62. Kern J.A., Schwartz D.A., Nordberg J.E.et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50:1990;5184-5187.
63. Kern J.A., Slebos R.J., Top B.et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 93:1994;516-520.
64. Kim Y.C., Park K.O., Kern J.A.et al. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer. 22:1998;181-190.
65. Tsai C.M., Chang K.T., Perng R.P.et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst. 85:1993;897-901.
66. Tsai C.M., Yu D., Chang K.T.et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 87:1995;682-684.
67. Tsai C.M., Chang K.T., Wu L.H.et al. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. 56:1996;206-209.
68. Tsai C.M., Chang K.T., Chen J.Y., Chen Y.M., Chen M.H., Perng R.P. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res. 56:1996;794-801.
69. Yu D., Wang S.S., Dulski K.M., Tsai C.M., Nicolson G.L., Hung M.C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 54:1994;3260-3266.
70. Levitzki A., Gazit A. Tyrosine kinase inhibition. an approach to drug development Science. 267:1995;1782-1788.
71. Hidalgo M., Siu L.L., Nemunaitis J.et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279.
72. Negoro S, Nakagawa K, Fukuoka M, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in japanese patients with various solid tumours. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1292).
73. Ranson M., Hammond L.A., Ferry D.et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2002;2240-2250.
74. Rowinsky EK, Hammond LA, Siu L, et al. Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinsae inhibitor. Proc Am Soc Clin Oncol 2001, 20(abstract No. 5).
75. Senzer NN, Soulieres SL, Siu L, et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2001, 20(abstract No. 6).
76. Goss GD, Hirte H, Lorimer I, et al. Final results of the dose escalation phase of a phase I pharmacokinetics (PK), pharmacodynamics (PD), and Biological activity study of ZD1839: NCIC CTG Ind.122. Proc Am Soc Clin Oncol 2001, 20(abstract No. 335).
77. Douillard J, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1195).
78. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1188).
79. Kris M, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum and docetaxel based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1166).
80. Natale RB, Skarin AT, Maddox AM, et al. Improvement in symptoms and quality of life for advanced non-small cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1167).
81. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20(abstract No. 1235).
82. Ciardiello F., Caputo R., Bianco R.et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063.
83. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 6:2000;4885-4892.
84. Kris M.G., Azzoli C.G., Miller V.A. Epidermal growth factor receptor blockade: targeted therapy for non-small cell lung cancer. Perry M.C. American Society of Clinical Oncology; 2002 Educational book. 2002;693-701 Lippincott Williams & Wilkins, Baltimore.
85. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002, 21(abstract No. 900).
86. Hong WK, Arquette MA, Nabell L, Needle MN, Waksal H, Herbst RS. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2001, 20(abstract No. 895).
87. Kies MS, Arquette MA, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin-containing chemotherapy. Proc Am Soc Clin Oncol 2002, 21(abstract No. 925).
88. Shin D.M., Donato N.J., Perez-Soler R.et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 7:2001;1204-1213.
89. Rosenberg AH, Loehrer PJ, Needle MN, et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002, 21(abstract No. 536).
90. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 referactory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20(abstract No. 7).
91. Schoffski P, Lutz MP, Folprecht G, et al. Cetuximab (C225) plus irinotecan (CPT-11) plus infusional 5FU-folinic acid (FA) is safe and active in metatstatic colorectal cancer (MCRC), that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002, 21(abstract No. 633).
92. Baselga J., Pfister D., Cooper M.R.et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914.
93. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53:1993;4637-4642.
94. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 8:2002;994-1003.
95. Raben D, Helfrich B, Chan D, et al. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer cells in vitro and in vivo. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1026).
96. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment. the emerging role of IMC-C225 in the treatment of lung and head and neck cancers Semin Oncol. 29:2002;27-36.
97. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1168).
98. Cobleigh M.A., Vogel C.L., Tripathy D.et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:1999;2639-2648.
99. Leyland-Jones B. Trastuzumab. hopes and realities Lancet Oncol. 3:2002;137-144.
100. Azzoli C.G., Krug L.M., Miller V.A., Kris M.G., Mass R. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol. 29:2002;59-65.
101. Langer CJ, Adak S, Thor A, Vangel M, Johnson D. Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzamab (T) in HER-2/neu (+) advanced non-small cell lung cancer (NSCLC): Early analysis of E2598. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1257).
102. Krug LM, Miller V, Crapanzano J, et al. Randomized phase II trial of trastuzamab (tras) plus either weekly docetaxel (doc) or paclitaxel (pac) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20 (abstract No. 1328).
103. Gatzemeier U, Groth G, Hirsch V, et al. Gemcitabine/cisplatin alone and with trastuzamab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study. Proc Am Soc Clin Oncol 2002, 21 (abstract No. 1185).
104. Zinner R.G., Kim J., Herbst R.S. Non-small cell lung cancer clinical trials with trastuzumab. their foundation and preliminary results Lung Cancer. 37:2002;17-27.
105. Hill B.T., Perrin D., Kruczynski A. Inhibition of RAS-targeted prenylation. protein farnesyl transferase inhibitors revisited Crit Rev Oncol Hematol. 33:2000;7-23.
106. Zhang F.L., Casey P.J. Protein prenylation. molecular mechanisms and functional consequences Annu. Rev. Biochem. 65:1996;241-269.
107. Schiller J.H., Adak S., Feins R.H.et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol. 19:2001;448-457.
108. Zachos G., Spandidos D.A. Expression of ras proto-oncogenes. regulation and implications in the development of human tumors Crit Rev Oncol Hematol. 26:1997;65-75.
109. Tamanoi F., Kato-Stankiewicz J., Jiang C., Machado I., Thapar N. Farnesylated proteins and cell cycle progression. J Cell Biochem. 37(Suppl):2001;64-70.
110. Rowinsky E.K., Windle J.J., Von Hoff D.D. Ras protein farnesyltransferase. A strategic target for anticancer therapeutic development J Clin Oncol. 17:1999;3631-3652.
111. Adjei A.A., Erlichman C., Davis J.N.et al. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 60:2000;1871-1877.
112. Eskens F.A., Awada A., Cutler D.L.et al. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 19:2001;1167-1175.
113. Evans TL, Fidias P, Skarin A, et al. A phase II study of efficacy and tolerability of the farnesyl-protein transferase inhibtorL-778,123 as first line therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1861).
114. Johnston SR, Hickish T, Houston S, Ellis PA, Howes AJ, Thibault A. Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 138).
115. Tabernero J, Sonnichsen D, Albanell J, et al. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 304).
116. Winquist E, Moore M.J., Chi K, et al. NCIC CTG IND.128 a phase II study of a farnesyltransferase inhibitor (SCH66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc Am Soc Clin Oncol 2001, 20(abstract No. 785).
117. Zujewski J., Horak I.D., Bol C.J.et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 18:2000;927-941.
118. Kies MS, Clayman G, El-Naggar AK, et al. Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 2001, 20(abstract No. 896).
119. Adjei AA, Mauer AM, Marks R, et al. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1156).
120. Cloughesy, T.F., Kuhn, J. and Wen, P., et al. Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing antiepileptic drugs (EIAED): A North American brain tumor consortium (NABTC) report. Proc Am Soc Clin Oncol 2002, 21 (abstract No. 21).
121. Harousseau J, Stone R, Thomas X, et al. Interim results from a phase II study of R 115777 (Zarnestra) in patients with relapsed and refractory acute myeloid leukemia. Proc Am Soc Clin Oncol 2002, 21 (abstract No. 1056).
122. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
123. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
124. O'Reilly M.S., Holmgren L., Shing Y.et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
125. O'Reilly M.S., Boehm T., Shing Y.et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
126. Good D.J., Polverini P.J., Rastinejad F.et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 87:1990;6624-6628.
127. Tolsma S.S., Volpert O.V., Good D.J., Frazier W.A., Polverini P.J., Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 122:1993;497-511.
128. Cox G., Walker R.A., Andi A., Steward W.P., O'Byrne K.J. Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer. 29:2000;169-177.
129. Fontanini G., Bigini D., Vignati S.et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol. 177:1995;57-63.
130. Fontanini G., Lucchi M., Vignati S.et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 89:1997;881-886.
131. Fontanini G., Boldrini L., Chine S.et al. Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer. 79:1999;363-369.
132. Giatromanolaki A., Koukourakis M.I., Kakolyris S.et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 4:1998;3017-3024.
133. Imoto H., Osaki T., Taga S., Ohgami A., Ichiyoshi Y., Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer. prognostic significance in squamous cell carcinoma J Thorac Cardiovasc Surg. 115:1998;1007-1014.
134. Koukourakis M.I., Giatromanolaki A., Thorpe P.E.et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 60:2000;3088-3095.
135. Niki T., Iba S., Tokunou M., Yamada T., Matsuno Y., Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res. 6:2000;2431-2439.
136. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A.et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer. 82:2000;1427-1432.
137. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases. balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med. 1:1995;149-153.
138. Gordon M.S. Vascular endothelial growth factor as a target for antiangiogenic therapy. J Clin Oncol. 18:2000;45. S-46S.
139. Gordon M.S., Margolin K., Talpaz M.et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 19:2001;843-850.
140. Margolin K., Gordon M.S., Holmgren E.et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 19:2001;851-856.
141. DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 2000, 19(abstract No. 1896).
142. Novotny W, Holmgren E, Griffing S, Johnson D, DeVore RF, Kabbinavar F. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving Bevacizumab (BV). Proc Am Soc Clin Oncol 2001, 20(abstract No. 1318).
143. Johnson DH, DeVore RF, Kabbinavar F, Herbst RS, Holmgren E, Novotny W. Carboplatin (C)+paclitaxel (T)+RhuMab-VEGF (AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1256).
144. Shepherd F.A. Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer. 34(Suppl 3):2001;S81-S89.
145. Fong T.A., Shawver L.K., Sun L.et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106.
146. Mendel D.B., Schreck R.E., West D.C.et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 6:2000;4848-4858.
147. Shaheen R.M., Davis D.W., Liu W.et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416.
148. O'Donnell AE, Trigo JM, Banerji U, et al. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast MRI assessment of vascular permeability. Proc Am Soc Clin Oncol 2000, 19(abstract No. 685).
149. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol 1999, 18(abstract No. 618).
150. Stopeck A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Proc Am Soc Clin Oncol 2000, 19(abstract No. 802).
151. Mesters R.M., Padro T., Bieker R.et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 98:2001;241-243.
152. Zahalsky AJ, Wong RJ, Lis E, et al. Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 902).
153. Kuenen B.C., Rosen L., Smit E.F.et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 20:2002;1657-1667.
154. Hoekman K, Kuenen BC, Levi M, et al. Activation of the coagulation cascade and endothelial cell perturbation during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Proc Am Soc Clin Oncol 2002, 21(abstract No. 21).
155. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! J Clin Oncol 2002, 20, 1446-1448.
156. Raje N., Anderson K. Thalidomide - a revival story. N Engl J Med. 341:1999;1606-1609.
157. Bauer K.S., Dixon S.C., Figg W.D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55:1998;1827-1834.
158. Richardson P., Hideshima T., Anderson K. Thalidomide. emerging role in cancer medicine Annu. Rev. Med. 53:2002;629-657.
159. Fine H.A., Figg W.D., Jaeckle K.et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 18:2000;708-715.
160. Little R.F., Wyvill K.M., Pluda J.M.et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 18:2000;2593-2602.
161. Nathan P.D., Eisen T.G. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol. 3:2002;89-96.
162. Singhal S., Mehta J., Desikan R.et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1999;1565-1571.
163. Merchant JJ, Hammes LC, Larson ML, et al. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2000, 19(abstract No. 2130).
164. Sanchez-Forgach E, Gerson R, Serrano A, Villalobos A. Thalidomide in advanced cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1880).
165. Singhal S., Mehta J. Thalidomide in cancer. Biomed Pharmacother. 56:2002;4-12.
166. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1997;1260-1270.
167. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer. 2:2002;161-174.
168. Curran S., Murray G.I. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 189:1999;300-308.
169. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:1999;781-792.
170. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases. biologic activity and clinical implications J Clin Oncol. 18:2000;1135-1149.
171. Cai M., Onoda K., Takao M.et al. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res. 8:2002;1152-1156.
172. Passlick B., Sienel W., Seen-Hibler R.et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res. 6:2000;3944-3948.
173. Shou Y., Hirano T., Gong Y.et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer. 85:2001;1706-1712.
174. Suzuki M., Iizasa T., Fujisawa T.et al. Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in non-small-cell lung cancer. Invasion Metastasis. 18:1998;134-141.
175. Yamamura T., Nakanishi K., Hiroi S.et al. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer. 35:2002;249-255.
176. Giavazzi R., Taraboletti G. Preclinical development of metalloproteasis inhibitors in cancer therapy. Crit Rev Oncol Hematol. 37:2001;53-60.
177. Hidalgo M., Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 93:2001;178-193.
178. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer. trials and tribulations Science. 295:2002;2387-2392.
179. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 29:2002;78-86.
180. Macaulay V.M., O'Byrne K.J., Saunders M.P.et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res. 5:1999;513-520.
181. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer. a randomized trial J Clin Oncol. 19:2001;3447-3455.
182. King, J, Clingan P, Morris DL. Placebo control double-blind randomised clinical trial of the matrix metalloprotease inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastases (CRCLM): Significant survival advantage in patients with muskuloskeletal symptoms. Proc Am Soc Clin Oncol 2002, 21(abstract No. 537).
183. Shepherd FA, Giaccone G, Debruyne C, et al. Randomized double-blind placebo-controlled double blind trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC-CTG and EORTC study. Proc Am Soc Clin Oncol 2001, 20(abstract No. 11).
184. Sparano J, Bernardo P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomised phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: An Eastern Cooperative Oncology Group trial (E2196). Proc Am Soc Clin Oncol 2002, 21(abstract No. 173).
185. Bisett D, Von Pawel J, Mercier R, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat (P) in combination with gemcitabine (G) and cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1183).
186. Smylie M, Mercier R, Aboulafia D, et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20(abstract No. 1226).
187. Falardeau P., Champagne P., Poyet P., Hariton C., Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 28:2001;620-625.
188. Franqois B, Champagne P, Evans WK, et al. Phase I/II trials on the safety, tolerability and efficacy of AE-941 (Neovastat) in patients with solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 2861).
189. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J Clin Oncol. 16:1998;1207-1217.
190. Roth J.A., Grammer S.F., Swisher S.G.et al. P53 gene replacement for cancer - interactions with DNA damaging agents. Acta Oncol. 40:2001;739-744.
191. Chiba I., Takahashi T., Nau M.M.et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 5:1990;1603-1610.
192. Forgacs E., Zochbauer-Muller S., Olah E., Minna J.D. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res. 7:2001;6-13.
193. Takahashi T., Nau M.M., Chiba I.et al. p53: a frequent target for genetic abnormalities in lung cancer. Science. 246:1989;491-494.
194. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
195. Fujiwara T., Grimm E.A., Mukhopadhyay T., Cai D.W., Owen-Schaub L.B., Roth J.A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 53:1993;4129-4133.
196. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 86:1994;1458-1462.
197. Nguyen D.M., Wiehle S.A., Koch P.E.et al. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 4:1997;191-198.
198. Roth J.A. Modification of tumor suppressor gene expression and induction of apoptosis in non-small cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin. Hum Gene Ther. 7:1996;1013-1030.
199. Roth J.A., Nguyen D., Lawrence D.D.et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:1996;985-991.
200. Swisher S.G., Roth J.A., Nemunaitis J.et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;763-771.
201. Nemunaitis J., Swisher S.G., Timmons T.et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 18:2000;609-622.
202. Schuler M., Herrmann R., De Greve J.L.et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol. 19:2001;1750-1758.
203. Blaese R.M., Ishii-Morita H., Mullen C.et al. In situ delivery of suicide genes for cancer treatment. Eur J Cancer. 30A:1994;1190-1193.
204. Roth J.A., Cristiano R.J. Gene therapy for cancer. what have we done and where are we going? J Natl Cancer Inst. 89:1997;21-39.
205. Singhal S., Kaiser L.R. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am. 7:1998;505-536.
206. Ishii-Morita H., Agbaria R., Mullen C.A.et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 4:1997;244-251.
207. Anonymous. Human gene marker/therapy clinical protocols (complete updated listing). Hum Gene Ther 2001, 12, 2251-2337.
208. Rosenfeld M.E., Curiel D.T. Gene therapy strategies for novel cancer therapeutics. Curr Opin Oncol. 8:1996;72-77.
209. Escudier B, Le Chevalier T, Angevin F, et al. Gene therapy with intratumoral (IT) injection of adenovirus expressing the IL2 gene (rAd-IL2) in lung cancer: results of a phase I study. Lung Cancer 2000, 29(suppl 1) (abstract No 626).
210. Nemunaitis J, Sterman D, Jablons D, et al. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001, 20 (abstract No. 1019).
211. Albelda S.M., Wiewrodt R., Zuckerman J.B. Gene therapy for lung disease. hype or hope? Ann Intern Med. 132:2000;649-660.
212. Frederiksen K.S., Petri A., Abrahamsen N., Poulsen H.S. Gene therapy for lung cancer. Lung Cancer. 23:1999;191-207.
213. Zou Y., Zong G., Ling Y.H.et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst. 90:1998;1130-1137.
214. Zou Y., Zong G., Ling Y.H., Perez-Soler R. Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther. 7:2000;683-696.
215. Khuri F.R., Nemunaitis J., Ganly I.et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 6:2000;879-885.
216. Kubba S, Adak A, Schiller J, et al. Phase I trial of adenovirus p53 in bronchoalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage. Proc Am Soc Clin Oncol 2000, 19(abstract No. 1904).
217. Askari F.K., McDonnell W.M. Antisense-oligonucleotide therapy. N Engl J Med. 334:1996;316-318.
218. Tamm I., Dorken B., Hartmann G. Antisense therapy in oncology. new hope for an old idea? Lancet. 358:2001;489-497.
219. Coudert B., Anthoney A., Fiedler W.et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur J Cancer. 37:2001;2194-2198.
220. Dang T, Johnson DH, Kelly K, Rizvi N, Holmlund J, Dorr A. Multicenter phase II trial of an antisense inhibitor of H-ras (ISIS-2503) in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1325).
221. Yuen A.R., Halsey J., Fisher G.A.et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 5:1999;3357-3363.
222. Nemunaitis J., Holmlund J.T., Kraynak M.et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol. 17:1999;3586-3595.
223. Hosomi Y., Yokose T., Hirose Y.et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 30:2000;73-81.
224. Achiwa H., Yatabe Y., Hida T.et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 5:1999;1001-1005.
225. Khuri F.R., Wu H., Lee J.J.et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 7:2001;861-867.
226. Teicher B.A., Korbut T.T., Menon K., Holden S.A., Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol. 33:1994;515-522.
227. Hida T., Leyton J., Makheja A.N.et al. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 18:1998;775-782.
228. Hida T., Kozaki K., Muramatsu H.et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 6:2000;2006-2011.
229. Tsubouchi Y., Mukai S., Kawahito Y.et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 20:2000;2867-2872.
230. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc Am Soc Clin Oncol 2002, 21(abstract No. 101).
231. Csiki I, Dang A, Gonzalez A, et al. Cyclooxygenase-2 (COX-2) inhibition+docetaxel (txt) in recurrent non-small cell lung cancer (NSCLC): Preliminary results of a phase II trial (THO-0054). Proc Am Soc Clin Oncol 2002, 21(abstract No. 1187).
232. Figlin RA, Belldegrun AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase I clinical results. Proc Am Soc Clin Oncol 2002, 21(abstract No. 35).
233. Tewes M, Schleucher N, Dirsch O, et al. Results of a phase I trial of the humanized anti epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in patients with EGFR expressing solid tumors. Proc Am Soc Clin Oncol 2002, 21(abstract No. 378).
234. Rinehart JJ, Wilding G, Willson J, et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21(abstract No. 41).
235. Zinner RG, Donato NJ, Nemunaitis J, et al. Biomarker modulation in tumor and skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Proc Am Soc Clin Oncol 2002, 21(abstract No. 58).
236. Olson S, Baker L, Cunningham CC, et al. A population pharmacokinetic (PPK) analysis of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002, 21(abstract No. 361).
237. Garrison MA, Tolcher A, McCreery H, et al. A phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on days 1,8, and 15 every 28 days to patients with solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 283).
238. Shin DM, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001, 20(abstract No. 324).
239. Schiller J, Hammond LA, Carbone D, et al. Phase 2A trial of squalamine for treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001, 20(abstract No. 1353).
240. Blumenschein GR, Fossella F, Pisters KM, et al. A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol 2002, 21(abstract No. 1254).